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RESEARCH ARTICLE
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Abstract
High-fat diet-induced obesity (DIO) is associated with fatty liver and elevated IL-6 circulating
levels. IL-6 administration in rodents has yielded contradictory results regarding its effects
on steatosis progression. In some models of fatty liver disease, high doses of human IL-6
ameliorate the liver steatosis, whereas restoration of IL-6 in DIO IL-6-/- mice up-regulates
hepatic lipogenic enzymes and aggravates steatosis. We further examined the effects of
chronic low doses of murine IL-6 on hepatic lipid metabolism in WT mice in DIO. IL-6 was
delivered twice daily in C57BL/6J DIO mice for 15 days. The status and expression of IL-6-
signalling mediators and targets were investigated in relation to the steatosis and lipid con-
tent in blood and in liver. IL-6 administration in DIO mice markedly raised circulating levels
of lipids, glucose and leptin, elevated fat liver content and aggravated steatosis. Under IL-6
treatment there was hepatic Stat3 activation and increased gene expression of Socs3 and
Tnf-alpha whereas the gene expression of endogenous IL-6, IL-6-receptor, Stat3, Cpt1
and the enzymes involved in lipogenesis was suppressed. These data further implicate IL-6
in fatty liver disease modulation in the context of DIO, and indicate that continuous stimula-
tion with IL-6 attenuates the IL-6-receptor response, which is associated with high serum
levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic
enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that
observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.
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Introduction
Increased plasma IL-6 levels are normally associated with obesity and fatty liver disease [1–4],
but the involvement of IL-6 in the molecular mechanisms underlying the pathogenesis of lipid
and carbohydrate metabolism is not fully understood [5–7]. Indeed, it is a subject of excited
debate in the literature [8–13]. Regarding hepatic lipid metabolism, evidence suggests that IL-6
affects the degradation as well as synthesis of fatty acids [10, 12, 14–18]. The fact that cytokines,
such as IL-6, are subjected to a rigorous signalling feedback control and that some of them can
share their receptor chains and signalling pathways may complicate the interpretation of the
role of a cytokine in a given scenario [19, 20].
Previous studies have shown a beneficial role of IL-6 against several models of fatty liver,
including alcohol liver disease [10, 21–23]. Moreover, the lack of IL-6 predisposes to liver stea-
tosis, thus reinforcing a priori the idea that IL-6 contributes to alleviating steatosis [12, 22, 24].
These beneficial effects were attributed in part to the ability of IL-6 to mediate mitochondrial
beta-oxidation of fatty acids, increase the hepatic export of triglycerides and cholesterol, and to
its antioxidant, anti-apoptotic effects on hepatocytes [10, 17, 18, 21].
From the above, although one could infer that IL-6 has a protective role in fatty liver dis-
eases, it is nevertheless striking that both alcoholic and non-alcoholic fatty liver diseases
(NAFLD) are associated with elevated serum levels of IL-6 as well as increased blood concen-
trations of lipids and glucose [1, 25, 26]. Likewise, high doses of IL-6 increase blood levels of
lipids and glucose [27–29]. Indeed, in chronic inflammatory autoimmune diseases such as
rheumatoid arthritis, in which the production of IL-6 is deregulated, the circulating lipid levels
(total cholesterol and triglycerides) are increased while blockade of IL-6 decreases their levels
[30]. In a recent study we showed that the chronic replacement of IL-6 with physiological
doses in IL-6-/- mice seriously aggravates the steatosis induced by a high-fat diet [12]. This
effect was accompanied by the up-regulation of the lipogenic enzymes, thereby possibly con-
tributing to fatty acid accumulation through de novo production in the liver of these mice [12].
Thus, the question also arises concerning whether the higher levels of lipogenic enzymes in the
liver are related to high levels of circulating IL-6.
IL-6 acts via the gp80/gp130 complex which is expressed mainly in leukocytes and those
cells where fatty acid synthesis occurs, as adipocytes and hepatocytes [31, 32]. IL-6 binds ini-
tially to the non-signalling interleukin-6 receptor (IL-6R or gp80), which subsequently leads to
the recruitment of two gp130 receptor proteins. The IL-6 receptor complex promotes activa-
tion of the signal transducer and activator of transcription 3 (Stat3) through the Jak kinase
[19]. Once Stat3 is tyrosine phosphorylated (activated) it translocates as a dimer into the
nucleus, where it activates specific genes [33]. Recent studies have revealed that mRNA levels
of the lipogenic enzymes acetyl-CoA carboxylase (Acac) and fatty acid synthase (Fasn) are
increased through the hepatic over-expression of Stat3 [34]. Interestingly, treatment of mice
with IL-6 increases the levels of Stat3mRNA in the liver [35]. Moreover, we reported that the
gene expression of the lipogenic enzymes Acac, Fas and Stearoyl-CoaA desaturase (Scd1) was
no longer up-regulated by IL-6 in the presence of siRNA Stat3 in hepatocytes, therefore indi-
cating that IL-6-mediated signalling promotes the expression of these enzymes via activation
of Stat3 [36].
Inhibition of the Stat3 pathway can occur by two main elements: the suppressor of the cyto-
kine signalling 3 (Socs3) protein, which acts through inhibition of Jak/Stat at the level of the
IL-6 receptor in the membrane; and by the protein inhibitor of activated Stat3 (Pias3), which
inhibits Stat3/DNA binding in the nucleus [20]. The mRNA for Socs3 is rapidly induced upon
IL-6 stimulation and its protein inhibits IL-6-mediated signalling in a classic feedback loop.
Socs3 deficiency results in prolonged activation of Stat3 after IL-6 stimulation and,
High Levels of IL-6 Desensitizes IL-6 Response
PLOS ONE | DOI:10.1371/journal.pone.0157956 June 22, 2016 2 / 19
Junta Andalucía (PI0552, PI0228-2013 and PI0823-
2012). Samir Badran received an Erasmus+ mobility
grant EU funds (code ID:DK ESBEJRG19). Juan
Suarez, Antonia Serrano and F. Javier Pavón
received a "MiguelServet" research contract and
grant from the National System of Health, Instituto de
Salud Carlos III, (grants number CP12/03109, CP14/
00212, CP14/00173, respectively). Elena Baixeras
received an I3SNS contract from Program of the
Instituto de Salud Carlos III and Andalusian
"Progreso y Salud" Foundation, Spain. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
interestingly, also promotes lipogenesis, thereby leading to fat accumulation and inflammation
in the liver [37, 38]. The interaction of Pias proteins with Stat factors requires tyrosine phos-
phorylation (activation) of the Stat proteins [39]. Thus for example, Pias3 inhibits the gene
expression mediated by phosphorylated Stat3 after IL-6 stimulation [39].
In a recent study we observed that a single low dose of IL-6 up-regulated the gene expression
of lipogenic enzymes in IL-6-/- mice under a normal chow diet [36]. However, notably, this
phenomenon was less obvious in the corresponding counterpart wild-type (WT) mice, which
appeared less receptive to IL-6 treatment [36]. Interestingly, the repeated administration of
human IL-6 to WT mice causes complete remission of the fatty liver diseases [10, 21, 22]
whereas the replacement of IL-6 in IL6-/- mice with fatty liver aggravates the steatosis [12].
These two opposing biological actions of IL-6 in WT and IL-6-/- mice highlight the fact that the
role of IL-6 in metabolic liver disease is not completely understood.
In this study we further explore the effects of chronic administration of IL-6 in WTmice in
a situation of diet-induced obesity (DIO), a situation that already increases the endogenous cir-
culating IL-6 levels and induces fatty liver. The results presented herein indicate that, the
administration of exogenous IL-6 in WTmice worsened the steatosis. However, the expression
of hepatic lipogenic enzymes remained strongly reduced. The findings suggest a mechanism
for desensitizing IL-6-mediated signalling in order to abolish the continuous stimulation of the
IL-6-receptor in a WT background. This phenomenon may not only have implications in the
modulation of the severity of the steatosis but it may also help to understand the controversial
data about the role of IL-6 in the liver.
Material and Methods
Animals and ethical statement
The experiments were performed on 12 week-old male mice from the C57BL/6J (SN 0664)
strain (Charles River Laboratories, Barcelona, Spain). The mice were housed with a 12 hour—
12 hour light/dark cycle and fed a standard chow diet ad libitum. Water and chow pellets were
available ad libitum throughout the course of the present study.
Mice were split in two groups: one group fed a regular chow diet (STD; Harlam Teklad,
MadisonWI) for 16 weeks, and a second group fed a high-fat diet (HFD, diet-D12492; Research
Diets Inc., New Brunswick, NJ, USA) for 16 weeks. After 16 weeks of HFD feeding, the mice
were chronically treated with either murine recombinant IL-6 (rIL-6, Peprotech, Inc., Rocky Hill,
NJ, USA) or vehicle (0.1% BSA in PBS) alone as previously described [12]. For some experiments
IL-6-deficient (IL-6-/-) mice, strain B6.129S2-IL-6tm1Kopf/J (SN 2650, http://jaxmice.jax.org/
strain/002650.html), were also included. Since the levels of lipogenic enzymes in liver may vary
depending on the time of food intake or fasting [36], both strains were maintained in the same
feeding/fasting conditions. The day of sacrifice, animals were fasted from 08:00 h. The mice were
treated with the last inoculation of rIL-6 or vehicle at 12:00 h and were sacrificed 1 hour later.
All experimental procedures with animals were conducted in accordance with the Spanish
Legislation (Real Decreto 53/2013, BOE, 34/-11421, 2013) in compliance with the European
Community Directive 2010/63/EU regulating the use and care of laboratory animals. The pro-
tocols were approved by the Ethics Committee (Permit number: 2012-0070-A) for Animal
Experiments of the University of Malaga. The animals were anaesthetized using isoflurane to
minimize animal suffering before sacrificing via decapitation.
Blood sampling, and serum biochemical and cytokine analysis
Blood sample collection was performed as previously described [12]. The IL-6 and leptin con-
centrations in the sera were assayed using ELISA kits specific for the mouse IL-6 (Millipore,
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Temecula, CA, USA), and leptin (Abcam, Cambridge, UK) according to the manufacturer’s
instructions. Biochemical parameters were assessed as previously described [12].
Histological evaluation and liver fat extraction
Liver samples embedded in paraffin were sectioned into 3 μm slices and deparaffinized in
xylene followed by haematoxylin and eosin (H&E) stainning. Total fat was extracted from the
liver and assessed as previously described [12, 40].
RNA isolation, RT-qPCR analysis
Total RNA from liver sections was extracted and reverse transcribed as described [12]. The
expression of the genes encoding for mouse Acc-alpha (Acaca), Acc-beta (Acacb), Fas (Fasn),
Scd1 (Scd1), Cpt1 (Cpt1), Tnf-alpha (TNF-alpha) Socs3 (Socs3), Srebp-1(Srebp-1) and Lxr (Lxr)
was measured through qPCR by using FastStart Universal SYBR Green Master (Rox) (Roche
Applied Science, Mannheim, Germany). Mouse glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) and mouse beta-glucuronidase (Gus-beta) were used as reference genes. Specific oligo-
nucleotides were designed at Universal Probe Library (Roche Applied Science) to amplify par-
ticular regions of the genes of interest. Specific primers for the mouse IL-6 gene as well as the
reference genes Gapdh and Gus-beta were obtained from Taqman1 Gene Expression Assays
(Life Technologies). The gene symbols, GeneID, primer sequences and amplicon lengths, except
those for Stat3, are described elsewhere [12, 36]. For mouse Stat3 (Gene ID: 20848) expression
the following primers were used:mStat3 forward GTTCCTGGCACCTTGGATT and reverse
CAACGTGGCATGTGACTCTT. All PCR reactions were performed using a CFX96 Real-Time
PCR Detection System (Bio-Rad, Hercules, CA, USA) and Cq and efficiency value calculation
for each experimental set was performed as described [12]. The calibrated normalized relative
quantity values were exported from the qBasePLUS software and statistically analyzed.
Protein Extraction andWestern Blot Analysis
The protein extraction and western blot analysis were performed as described [12]. Specific
proteins were detected after incubation of blotted membranes with the corresponding pri-
mary antibodies: rabbit anti-Acc-alpha/beta, anti-Fas, anti-Scd1, anti-Stat3, anti-phospho-
Stat3 (Tyr705) and anti-Actin antibodies (Cell Signalling Technology Inc. MA, USA).
Rabbit anti-Cpt1A, anti-LepR and anti-adaptin gamma antibodies were purchased from
Abcam (Cambridge, UK), anti-phospho LepR (Tyr 1077) antibody was from Millipore
(Temecula, CA, USA) and anti-Socs3 and anti-Pias3 antibodies were from Santa Cruz (Bio-
technology Inc., CA, USA). The specific protein bands were revealed using an anti-rabbit
HRP-conjugated antibody as secondary antibody (Promega, Madison, MI, USA) followed by
detection through the enhanced chemiluminescence system (Santa Cruz, Biotechnology Inc.
CA, USA) as described [12]. The levels of specific proteins were normalized to actin or adap-
tin levels.
Statistical analysis
All data in the graphs and tables are expressed as the mean ± standard error of the mean
(SEM). The GraphPad Prism version 5.04 software was used for statistical analysis of the
results (GraphPad Software Inc., San Diego, CA, USA). The significance of the differences
between groups (diet) was evaluated using one-way analysis of variance (ANOVA), followed
by a post hoc test for multiple comparisons (Bonferroni test). P-values less than 0.05 were con-
sidered statistically significant.
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Results
1. Chronic administration of IL-6 aggravates the steatosis and increases
serum leptin levels in wild-type mice in DIO
To further examine the effects of IL-6 in NAFLD we induced steatosis in WT mice with a HFD
for 16 weeks. In parallel, a group of mice were fed a STD. During this period, the group fed a
STD gained 10.5 g while the group fed a HFD gained 22 g and became obese. The HFD-fed
group was split in two subgroups: one subgroup was treated with saline (HFD) and the other
subgroup was treated with recombinant IL-6 (HFD+rIL-6) for an additional 15 days, as
described in Material and Methods. Fig 1A illustrates the liver histology of mice fed a STD, a
HFD, and a HFD treated with rIL-6. Livers from mice fed a STD showed a normal parenchyma
whereas those of HFD-fed mice had increased lipid content, exhibiting a moderate diffuse
macrovesicular steatosis. The fatty changes were more pronounced in HFD-fed mice treated
with rIL-6, resulting in a severe macro- and microvesicular steatosis, with predominant accu-
mulation of small lipid droplets in hepatocytes. No significant inflammatory (lymphocyte infil-
trates) reaction was seen. Fat storage was also measured by determining the total fat and
triglyceride contents in the liver (Fig 1B). Compared with the STD group, total fat was 2.3-fold
higher (P<0.05) in the HFD group and 4.3-fold higher (P<0.01) in the HFD group treated
with rIL-6 (Fig 1B). Likewise, the triglyceride content tended to increase (1.5-fold) in the livers
Fig 1. Effect of IL-6 chronic treatment on steatosis and fat liver content in WTmice fed a HFD. (A)
Representative histological appearance of the liver sections (haematoxylin and eosin-stained) frommice fed
a STD, HFD or HFD-treated with rIL-6 (HFD+rIL-6). The accumulation of lipid droplets is evident in the livers
of HFDmice, revealing moderate steatosis in HFD samples and marked and diffuse microvesicular and
macrovesicular steatosis in HFD+rIL-6 samples. Scale bars: 100 μm and 50 μm for x20 and x40
magnifications, respectively (B) Hepatic fat and triglyceride content in the samples frommice fed STD, HFD
or HFD+rIL-6. The values are presented as the means ± SEM (n = 8 samples per group), and differences
between diet conditions were evaluated using one-way ANOVA analysis. *P<0.05 and **P<0.01 denote
significant differences compared with the corresponding STD-fed group.
doi:10.1371/journal.pone.0157956.g001
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from HFD-fed mice, becoming significantly higher (2.8-fold; P<0.01) in livers from the HFD
group receiving rIL-6 (Fig 1B). The severity of fatty liver after a HFD was also associated with
significant increases in serum concentrations of cholesterol (1.5-fold, P<0.01) as compared
with the cholesterol levels found in STD-fed mice (Table 1). Cholesterol levels were signifi-
cantly higher (P<0.001) in the rIL-6 treated group, in which serum cholesterol concentrations
were increased 2-fold (P<0.001), compared with the STD group (Table 1). However, serum tri-
glyceride, HDL-cholesterol, GPT and GGT levels showed no significant changes in any of the
groups.
The circulating levels of glucose and the cytokines IL-6 and leptin were also measured in
serum of WT and IL-6-/- mice in DIO. As shown in Table 2, the basal blood glucose levels were
increased (P<0.05) in WT DIO mice after rIL-6 treatment, as they were in IL-6-/- DIO mice
without any treatment (P<0.01) (Table 2). Increased levels of IL-6 (5-fold; P<0.001) and leptin
(1.5-fold; P<0.05) were observed in the HFD-fed mice as compared with the STD group. The
treatment with rIL-6 not only markedly increased the serum levels of IL-6 (8-fold; P<0.001)
with respect to the STD group (as expected), but it also increased (3.6-fold, P<0.001) the circu-
lating leptin levels. This latter observation suggested that these mice developed leptin resis-
tance. This may seem somewhat paradoxical because hyperleptinemia and leptin resistance
have been described in obese IL-6-/- mice and are therefore associated with a lack of IL-6 rather
than increased levels of IL-6 [13]. Indeed, samples from mice deficient for IL-6 and maintained
in the same DIO conditions showed a marked increase in serum leptin levels as compared with
the corresponding STD-fed control group (Table 2).
We next investigated the expression of the leptin receptor (LepR) and its tyrosine phosphor-
ylation status (p-LepR) in the liver tissue of WT mice from the different groups. We found that
LepR phosphorylation was increased in the HFD-fed group despite detecting lower total pro-
tein levels (Fig 2). This observation might reflect receptor activation and degradation after
Table 1. Biochemical parameters in serum.
Cholesterol Triglycerides HDL GPT GGT
STD 86.25 ± 3.8 60.25 ± 10.4 21.00 ± 2.4 36.75 ± 3.8 8.25 ± 1.6
HFD 129.00 ± 7.6** 45.00 ±13.2 24.00 ± 2.1 40.00 ± 3.2 7.00 ± 1.2
HFD +rIL-6 171.00 ± 6.3*** 47.00 ± 11.6 20.00 ± 1.2 36.00 ± 2.1 8.00 ± 1.2
*** P<0.001 vs STD
**P<0.01 vs STD
doi:10.1371/journal.pone.0157956.t001
Table 2. Levels of IL-6, leptin and glucose in serum.
IL-6 (pg/ml) Leptin (pg/ml) Glucose (mmol/l)
WT STD 18.22 ± 0.3 250.96 ± 10.1 135 ± 19
WT HFD 89.57 ± 4.5*** 368.00 ± 21* 131 ± 17
WT HFD +rIL-6 145.35 ± 3.6*** 896.84 ± 40.1*** 198 ± 9.9*
IL-6-/- STD _ 204.48 ± 9.9 230 ± 16
IL-6-/- HFD _ 928.19 ± 1.9 ### 309 ± 7.64##
*P<0.05 vs WT STD
*** P<0.001 vs WT STD
## P<0.01 vs IL-6-/- STD
### P<0.001 vs IL-6-/- STD
doi:10.1371/journal.pone.0157956.t002
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binding to ligand. The HFD-fed mice treated with rIL-6 showed reduced pLepR/LepR ratio,
thus suggesting a lesser LepR activity. Given that this animal group showed high levels of circu-
lating leptin, this last observation is compatible with a leptin resistance after rIL-6 treatment.
2. Chronic administration of IL-6 down-regulates the expression of the
hepatic enzymes of fatty acid metabolism in the DIO wild-type mice
The results described above are in line with the situation found previously in IL-6-/- mice in
which the chronic restitution of IL-6 aggravated the steatosis rather than improving it [12]. In
that case, the aggravation of steatosis observed after treatment with IL-6 was accompanied by
up-regulation of lipogenic enzymes [12]. Here we show that WT mice fed a HFD experience
no major changes regarding the hepatic Acaca, Acacb and Fasn levels, but a significant decrease
(P<0.01) in Scd1 expression as compared with the levels found in the STD condition (Fig 3A).
Unlike in the IL-6-/- mice, the treatment with rIL-6 in the WT mice in DIO significantly
reduced (P<0.05) the expression of Acaca, Acacb, and the expression of Scd1 was reduced even
further (P<0.001) (Fig 3A). No major changes were observed, however, for Fasn expression in
any of the diet conditions assayed, even in samples from mice treated with rIL-6 (Fig 3A).
Interestingly, the gene expression profile of the lipogenic enzymes was very similar to that
described previously for IL-6-/- mice in DIO and untreated with rIL-6 [12]. The protein expres-
sion of Acc-alpha/beta, Fas and Scd1 was also examined through western blotting (Fig 3B).
Paralleling their gene expression, exposure to a HFD did not change the expression of the
hepatic Acc-alpha/beta doublet or Fas levels, except for that of Scd1 which was reduced
(P<0.001) compared with the STD group (Fig 3B). A significant reduction (P<0.05) in the
expression of the Acc-alpha/beta doublet and Fas enzymes was observed in samples from mice
fed a HFD and treated with rIL-6, and levels of the Scd1 enzyme were further reduced (Fig 3B).
The transcription factors Srebp-1 and Lxr are involved in controlling the levels of lipogenic
gene enzymes [41]. Therefore, the Srebp-1 and Lxrα expression was examined in mice fed STD
or HFD. An increase in the Srebp-1 expression was observed in animals fed HFD and the treat-
ment with rIL-6 in this last group further increased these levels (S1 Fig). No major changes
were observed for Lxr expression in any of the nutritional and treatment conditions. These last
results indicated that the down-regulated expression of lipogenic enzymes observed after rIL-6
treatment could not be attributed to a negative expression of the Srebp-1 and Lxr factors.
IL-6 treatment in vivo increases the expression of the hepatic transcription factor Ppar-
alpha which regulates the expression of Cpt1 gene enzyme, which in turn is involved in the
beta-oxidation of fatty acids [10, 18, 42]. To further understand the molecular mechanisms
underlying the IL-6 aggravation of fatty liver we also examined the Ppar-alpha expression and
the expression of its target gene Cpt1. Compared with the group fed a STD, no changes were
observed for Ppar-alpha expression profile after HFD exposure, though the subsequent treat-
ment with rIL-6 up-regulated (P<0.05) its expression (Fig 4A). The Cpt1 expression showed a
significant (P<0.05) increase after a HFD but it was not increased after treatment with rIL-6
(Fig 4A). Likewise, analysis of the protein amounts revealed that Cpt1 was increased in the
HFD group but not in the rIL-6-treated HFD group (Fig 4B). Contrary to what was expected,
these last observations indicate that most probably the activity of Ppar-alpha was repressed
after the chronic treatment with rIL-6.
3. Chronic administration of rIL-6 affects endogenous IL-6 expression
negatively and increases Tnf-alpha expression in liver of DIO mice
Recent studies showed that IL-6-/- mice exhibited signs of liver inflammation [5], and when the
IL-6R was deleted only in hepatocytes, mice developed liver inflammation, which could be
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Fig 2. Leptin receptor (LepR) expression and Tyr (1077) phosphorylation status in liver of HFD-fedmice untreated or treated
chronically with rIL-6. Representative western blot analysis for total LepR and its phosphorylated form (p-LepR) out of five samples per
group (STD, HFD and HFD+rIL-6). The corresponding expression of actin is shown as loading control per lane. The ratios for LepR/actin and
p-LepR/LepR determined through densitometry are shown in the histograms below. The values represent the means ± SEM. The
significance of differences between groups was evaluated using one-way ANOVA. *P< 0.05 and **P< 0.01 denote differences compared
with the STD group, ##P< 0.01, denotes differences compared with HFD group.
doi:10.1371/journal.pone.0157956.g002
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Fig 3. Effect of IL-6 treatment on the expression of lipogenic enzymes in the livers of WTmice fed a
HFD. (A) The gene expression of Acaca, Acacb, Fasn, and Scd1 in the livers of WT fed STD, HFD or HFD-
treated chronically with rIL-6 (HFD+rIL-6) is depicted in the corresponding histogram. The gene expression
was determined through qPCR analysis of the liver samples. The expression of each gene was normalized
using Biogazelle’s qBasePLUS software withGapdh andGus-beta as reference genes. The columns
represent CNRQmeans ± SEM (n = 8 animals per group). (B) Western blot analysis of the protein expression
of Acc-alpha/beta, Fas, and Scd1 in liver samples fromWT and mice fed a STD, HFD or HFD+rIL-6.
Representative blots of each protein from two samples out of five per group are presented in the upper panel.
The corresponding expression of adaptin is shown as a loading control per lane. The histograms below blots
depict the levels of each Acc-alpha/beta, Fas and Scd1 protein determined through densitometry and
corrected for adaptin. The values represent the means ± SEM (n = 8 samples per group). Comparisons
High Levels of IL-6 Desensitizes IL-6 Response
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between diet conditions for each gene/protein in A and B were analyzed using one-way ANOVA. *P<0.05,
**P<0.01 and ***P<0.001 denote significant differences compared with the corresponding STD-fed group.
doi:10.1371/journal.pone.0157956.g003
Fig 4. Effect of IL-6 treatment on the expression of Ppar-alpha and its target geneCpt1 in the livers of
WTmice fed a HFD. The qPCR analysis for the gene expression of Ppar-alpha andCpt1 (A) in the livers of
mice fed STD, HFD or HFD+rIL-6 is depicted in the histogram. The expression of each gene was normalized
using Biogazelle’s qBasePLUS software withGapdh andGus-beta as reference genes. The columns
represent CNRQmeans ± SEM (n = 8 animals per group). (B) Western blot analysis of Cpt1 protein
expression in liver of mice fed a STD, HFD or HFD+rIL-6 is shown in the upper panel. Representative blots of
each protein from one sample out of eight per group are presented. The corresponding expression of actin is
shown as a loading control per lane. The histogram below the blot depicts the levels of Cpt1 determined
through densitometry corrected for actin. Comparisons between diet conditions were analyzed using one-
way ANOVA. *P<0.05, **P<0.01 denote significant differences compared with the corresponding STD-fed
group. #P<0.05 denotes significant differences in expression between HFD-fed and HFD+rIL-6 groups.
doi:10.1371/journal.pone.0157956.g004
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reduced by Tnf-alpha blockade, suggesting a pivotal balance of IL-6 and Tnf-alpha signalling
in the liver [43]. Previously we also determined that the chronic administration of rIL-6 was
able to inhibit the up-regulation of Tnf-alpha found in liver of IL-6-/- mice fed a HFD [12]. Fol-
lowing this, we analyzed the effects of IL-6 administration on the modulation of the gene
expression of the endogenous IL-6 and Tnf-alpha in the liver of WT mice subjected to DIO. In
agreement with previous studies [12], DIO mice showed an increased expression of endoge-
nous IL-6 but no major changes in Tnf-alpha levels (Fig 5). However, the subsequent chronic
administration of rIL-6 significantly reduced the levels of hepatic IL-6 whereas it up-regulated
the levels of Tnf-alpha (Fig 5). Thus, the Tnf-alpha may have been produced locally, thereby
exerting a restricted response in liver.
4. Chronic administration of rIL-6 during a HFD hampers gene up-
regulation of the IL-6R/gp130 complex and Stat3, and increases Socs3
amounts in liver
The results described in the previous sections suggested that IL-6 signalling was likely regulated
negatively in the presence of high amounts of rIL-6. This prompted us to analyze the expres-
sion and the status of the components of the IL-6-signalling transduction pathway in the con-
ditions assayed. First, we examined the regulation of IL-6R and gp130 gene expression under a
STD and a HFD. Feeding a HFD caused a 2-fold increase (P<0.05) in hepatic gene expression
of IL-6R, an effect that was not evident after IL-6 treatment (Fig 6A). A tendency to an
increased gp130 expression was observed in the HFD-fed group, but after chronic treatment
with rIL-6 the levels of gp130 chain expression returned to baseline levels and a post hoc test
showed significant (P<0.05) differences between the HFD and HFD+rIL-6 groups (Fig 6A).
Stat3, the main component of the IL-6-mediating signalling machinery, has been described
as a transcription factor contributing to the up-regulation of the lipogenic enzymes in hepato-
cytes [19, 34, 36]. Thus, we next assessed the effects of the exogenous administration of IL-6 on
the gene expression and activation status of Stat3. A modest 1.4-fold increase (P<0.05) in Stat3
expression was observed in the HFD-fed group with respect the STD-fed group. This up-regu-
lation was not found in the HFD+rIL-6 group, which showed basal levels of Stat3. Indeed, a
Fig 5. Effect of chronic administration of IL-6 on the hepatic expression of IL-6 and Tnf-alpha in the
livers of WTmice fed a HFD. Endogenous expression of the genes IL-6 and Tnf-alpha in liver samples from
mice fed STD, HFD or HFD+rIL-6, determined through qPCR analysis. Normalization was performed by
Biogazelle’s qBasePLUS software withGapdh andGus-beta as reference genes. The columns represent
CNRQmeans ± SEM (n = 8 animals per group) and the significance of differences between groups was
analyzed by one-way ANOVA. *P<0.05 denotes significant differences compared with the corresponding
STD-fed group.
doi:10.1371/journal.pone.0157956.g005
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Fig 6. Effect of chronic IL-6 treatment on the expression of components of the IL-6-signalling
transduction in liver of WTmice fed a HFD. (A)Gene expression of IL-6R, gp130 and Stat3 in the livers of
mice fed STD, HFD or HFD+rIL-6 determined through qPCR analysis. Normalization was done using
Biogazelle’s qBasePLUS software withGapdh andGus-beta as reference genes. The columns represent
CNRQmeans ± SEM (n = 8 animals per group). (B) Representative western blot analysis of one sample out
of eight of the hepatic expression of Stat3 and p-Stat3 in WTmice fed a STD, HFD or HFD+rIL-6. The
corresponding expression of actin is shown as loading control per lane. The histograms below the blots
depict the ratios for p-Stat3/Stat3 and Stat3/actin determined through densitometry in each diet condition.
The values represent the means ± SEM (n = 8 samples per group). (C) Analysis by qPCR of Socs3 and Pias3
gene expression in livers of mice fed a STD, HFD or HFD+rIL-6. Normalization was done using Biogazelle’s
qBasePLUS software withGapdh andGus-beta as reference genes. The columns represent CNRQ
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post hoc test showed differences (P<0.01) between the HFD and HFD+rIL-6 groups (Fig 6A).
Likewise, an increase (P<0.01) in the ratio of the Stat3 band density to the actin band density
was observed in animals fed a HFD; nevertheless, the p-Stat3/Stat3 ratio, representing changes
in the phosphorylated form, showed no main differences compared to the control group (Fig
6B). Interestingly, the treatment with rIL-6 hampered the increase in the Stat3/actin ratio even
though the p-Stat3/Stat3 ratio was significantly enhanced (P<0.001), thus indicating that the
treatment with rIL-6 resulted in the increased activation of Stat3 (Fig 6B).
We next examined at gene and protein levels the regulation of Socs3 and Pias3, two potent
negative regulators of IL-6-signal transduction [20]. In the HFD-fed mice, the levels of hepatic
Socs3 were up-regulated 3-fold (P<0.05) compared with the levels found in the STD-fed group
(Fig 6C). The administration of exogenous IL-6 in HFD-fed mice increased the liver expression
of Socs3 12-fold (P<0.001) (Fig 6C). Analysis of the Pias3 expression showed no major varia-
tions in the expression levels in any of the diet conditions assayed (Fig 6C).
Although not significant, analysis of the Socs3 protein expression revealed a tendency to
lower protein amounts in samples from the group treated with rIL-6 (S2 Fig). This observation
indicated that either the mRNA levels of Socs3 remained stabilized or that the Socs3 protein
was being degraded rapidly. Nevertheless, whatever amount of Socs3 was expressed, it was evi-
dently not enough to completely hinder the phosphorylation of Stat3. Likewise, the western
blot analysis revealed no significant variations in protein Pias3 levels between groups (S2 Fig).
Discussion
Non-alcoholic fatty liver disease covers a spectrum of liver diseases, ranging from simple stea-
tosis to non-alcoholic steatohepatitis (NASH) and cirrhosis [44]. In our assay conditions, even
though chronic treatment with IL-6 aggravated the steatosis under a HFD, we observed no
important inflammatory manifestations (e.g., lymphocyte infiltration) in liver samples. These
observations are in agreement with a previous study in which we found that IL-6 replacement
in IL-6-/- mice fed a HFD aggravated the steatosis [12]. In that case, the IL-6 administration
restored the hepatic Stat3 phosphorylation under a HFD, as well as up-regulating the expres-
sion of the lipogenic enzymes and worsening the steatosis [12]. This is in agreement with our
recent findings showing that hepatic cells treated with siRNA Stat3 are no longer able to up-
regulate lipogenic enzyme genes after IL-6 exposure [36]. Indeed, the depletion of liver Socs3,
the negative regulator of Stat3 activation, has been shown to promote hepatic lipogenesis and
the development of NAFLD under DIO [13, 38]. Likewise, in the present study, we found that
chronic treatment with rIL-6 in WT DIO mice increased hepatic Stat3 phosphorylation and
exacerbated steatosis. However, unlike in the IL-6-/- mice, this was concomitant with the drop
in lipogenic enzyme expression at both gene and protein levels. Our analysis revealed that the
down-regulated expression of lipogenic enzymes after rIL-6 treatment could not be attributed
at least to a negative expression of the Srebp-1 and Lxr transcription factors, although a defect
in their transcriptional activity cannot be ruled out. Paradoxical IL-6 actions in both WT and
IL-6-/- phenotypes have also been observed in previous studies. Indeed, we have previously
described the up-regulation of lipogenic enzymes after a single low dose of IL-6 in IL-6-/- mice
fed a normal diet but the same effect was not so obvious in the WT mice [36]. Wallenious et al.
described the reduction of body weight after treatment with IL-6 in IL-6-/- mice whereas there
means ± SEM (n = 8 animals per group). For A, B and C the significance of differences between diet groups
was evaluated using one-way ANOVA and Bonferroni post-hoc tests. *P<0.05, **P<0.01 and ***P<0.001
denote significant differences in expression compared with the corresponding STD-fed group. #P<0.05 and
##P<0.01 denote significant differences in expression between HFD-fed and HFD+rIL-6 groups.
doi:10.1371/journal.pone.0157956.g006
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was no effect on WTmice [13]. These paradoxical actions of IL-6 in WT and IL-6-/- mice prob-
ably reflect different mechanisms concerning the modulation of the IL-6-mediated signalling
between the two genotypes. In this regard, studies showing that pre-stimulation with IL-6 ren-
ders cells less sensitive to further stimulation with IL-6 [45] would support the idea of a refrac-
tory response to IL-6 stimulation in the WT HFD-fed mice, which most likely is absent in the
IL-6-/- mice, which thereby become more receptive to IL-6 response.
Following the line of reasoning mentioned above we found in this study that: first, the Cpt1
at gene and protein levels, up-regulated in HFD conditions, was no longer up-regulated after
treatment with rIL-6 even though the animals were exposed to a HFD, thus suggesting a failure
in IL-6-mediated signalling. Since Cpt1 is involved in the beta-oxidation of fatty acids, its defi-
cit is compatible with exacerbated steatosis. Likewise, the inhibition of the lipogenic enzyme
expression shown here after IL-6 administration should, to a certain extent, compensate the
HFD-induced steatosis but it also suggests a failure in IL-6-mediated signalling. This is consis-
tent with the increase observed in serum cholesterol levels in mice fed a HFD and treated with
rIL-6 and with the tendency to lower serum triglyceride concentrations while increasing tri-
glyceride concentrations in the liver (Fig 1 and Table 1).
Second, the raised levels of circulating leptin found in DIO mice after repetitive administra-
tion of exogenous IL-6 suggests the development of leptin resistance. Interestingly, this is
indeed one of the characteristics of obese mice lacking IL-6 [13]. The finding that the high lep-
tin levels in WT DIO mice treated with IL-6 were comparable to those found in the IL-6-/- DIO
mice (Table 2) is consistent with a desensitization of the IL-6 response. Indeed, the analysis of
the LepR revealed a lower phosphorylation status in samples from HFD+rIL-6 group as com-
pared with the phosphorylation levels found in the HFD fed group (Fig 2). In addition, we
observed in DIO mice that the IL-6 treatment elevated peripheral glucose levels (Table 2),
which is in agreement with other studies in humans showing a correlation between increased
levels of IL-6 and increased blood glucose [27]. But again it is surprising that the total depletion
of IL-6 in DIO mice seemed also to cause an increase in blood glucose (Table 2), a finding
described also in old obese IL-6-/- mice [13]. Therefore, it seems that excess IL-6 causes similar
effects to total depletion of IL-6 in obese conditions. Also interesting is the fact that the pheno-
type observed in DIOWTmice treated with IL-6 is reminiscent of leptin-deficient animals
such as the obese Zucker rat model, which shows hyperleptinemia, increased amounts of IL-6
and glucose, and suffers dyslipidaemia, diabetes and steatosis [46], thus suggesting a tight link
between both IL-6 and the leptin signalling systems in the liver.
Third, IL-6 exerts an anti-inflammatory function through its inhibitory effects on Tnf-alpha
gene expression [47, 48]. We previously showed that IL-6-/- mice exposed to a HFD exhibited
up-regulation of hepatic Tnf-alpha and that chronic rIL-6 treatment lessened the extent of this
up-regulation [12]. Paradoxically, in the present study we found that HFD-fed mice exposed to
exogenous IL-6 showed a marked Tnf-alpha up-regulation. Again, this is compatible with
desensitization of the IL-6-mediated signalling pathway. Moreover, the Tnf-alpha response is
involved in the stabilization of Socs3mRNA [49].
Fourth, the prolonged Stat3 activation observed in the liver of IL-6-treated mice a priori
argues against efficient negative regulation of IL-6-mediated signalling. Analysis of the negative
regulator of IL-6 signalling, Socs3, revealed that after IL-6 treatment in DIO, the mice showed
a marked increase in Socs3 expression while the levels of its protein remained unchanged (Figs
5C, S1). The Tnf-alpha up-regulation found in liver of mice treated with rIL-6 would provide
an explanation for the discrepancy between high levels of the Socs3 mRNA and the apparent
normal levels of its protein [49]. Socs3 binds simultaneously to specific sites of the receptor
subunit gp130 and Jak2, thereby hampering Stat3 activation [50]. Shortly thereafter, Socs3
undergoes a precise post-transcriptional regulation, which rapidly induces degradation in the
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proteasome [37, 50]. Concerning our findings, we cannot exclude the possibility that Socs3
exerts its function before being rapidly degraded. Indeed, as Socs3 is known to contribute to
leptin resistance [51], the high levels of leptin found in serum of mice treated with rIL-6 could
reflect leptin receptor failure as a result of the Socs3 activity in these mice. It can also be argued
that Stat3 rephosphorylation after hours of exposure to IL-6 has been described even in the
continued presence of Socs3 [52]. Indeed, rephosphorylation of Stat3 has been suggested to
occur because interaction between Socs3 and the IL-6 receptor is somehow prevented [52].
Fifth, the phosphorylation status observed in Stat3 does not agree with either the down-regu-
lated expression of genes depending on IL-6/Stat3-mediated signalling (like those of the lipo-
genic enzymes) or the up-regulated expression of Tnf-alpha. This strongly suggests that even
Fig 7. Diagram representing a putative mechanistic model of the desensitizing of the IL-6-mediated signal in liver of DIOmice. IL-6
binds its IL-6R/gp130 receptor complex, resulting in its autophosphorylation at 5 tyrosine residues and the activation of Jak which then induces
the recruitment of the Stat3 and its phosphorylation. The phosphorylated Stat3 dimerizes and migrates to the nucleus to initiate transcription of
Stat3-dependent genes, e.g., lipogenic genes, IL-6, Stat3, IL-6R/gp130, Ppar-alpha, and Socs3. Induced Socs3 protein is recruited to the
phosphotyrosine 759 (Y-759) motif of the activated gp130 and inhibits JAK activity. Nevertheless, as proposed elsewhere, IL-6 may overcome
Socs3 inhibition because there are 4 additional tyrosine phosphorylation sites in gp130, distal to the Tyr759 residue, that could allow ligand-
mediated Stat3 phosphorylation in vivo [19]. The Pias3 protein, which is normally expressed constitutively, may act like a buffer that titrates the
concentration of activated Stat3 dimers within the cell [20] thereby attenuating the Stat3 function. As a result, the transcription of Stat3-dependent
genes is suppressed, and subsequently the Tnf-alpha gene, which is down-regulated in liver by IL-6, is therefore induced. The locally produced
Tnf-alpha can mediate the Socs3mRNA stabilization [49]. Although the Socs3 protein can be rapidly degraded [37, 50], it inhibits the leptin
response therefore leading to leptin resistance [51]. Altogether, this would lead to the phenotype described in the IL-6-/- DIO mice showing
dyslipidaemia, elevated leptin, hyperglycaemia, and aggravated liver steatosis, as occurs in obese leptin-deficient animals [12, 46].
doi:10.1371/journal.pone.0157956.g007
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though Stat3 is phosphorylated, the Stat3 DNA binding activity is somehow dampened in our
model. Indeed, the transcription of IL-6-dependent genes, like endogenous IL-6, IL-6R/gp130
complex, Stat3, lipogenic enzymes, and Cpt1 [12, 35, 53], is down-regulated in the liver of mice
fed a HFD and treated with IL-6. A plausible explanation for these observations is the involve-
ment of Pias3, which interacts specifically with the phosphorylated form of the Stat3 molecules
after IL-6 stimulation, thereby negatively affecting its transcriptional activity [39]. The constitu-
tive expression of Pias3 shown here is consistent with the notion that its physiological function
differs from that of Socs3, which is induced in a negative feedback loop on cytokine stimulation.
It has been proposed that Pias3 protein may act like a buffer that titrates the concentration of
activated Stat3 dimmers within the cell [20]. Consequently, as outlined in Fig 7, it can be specu-
lated that binding of Pias3 to phosphorylated Stat3 accounts for the inhibited expression of the
IL-6-signalling pathway target genes in the liver of DIOmice after chronic IL-6 treatment.
Conclusions
Overall, our results suggest that both deficiency and excess of IL-6 can lead to similar effects,
particularly in the context of fatty liver disease. This paradox is probably the result of adjust-
ments in signal transduction pathways to compensate for the imbalanced concentrations of the
IL-6. As proposed elsewhere, whether the IL-6 effects were “good or evil” seems to depend on
the site, the time of production, the amounts, and the metabolic context [8]. The present results
underscore the importance of the duration of exposure to IL-6, even at low levels, on desensiti-
zation of the IL-6 receptor in relation to progression of NAFLD in a WT context. In summary,
it is quite possible that the high circulating levels of IL-6 observed in obesity generate, in turn,
the down-modulation of the signalling pathway of IL-6 and ultimately a deficit of its signal,
producing an IL-6-deficient like situation reminiscent of that found in obese IL-6-/- mice and
obese Zucker rat models.
Supporting Information
S1 Fig. Gene expression of Srebp-1 and Lxrα in the livers of WTmice fed HFD and treated
with rIL-6. The gene expression of Srebp-1 and Lxrα in the livers of WT fed STD, HFD or
HFD-treated chronically with rIL-6 (HFD+rIL-6) is shown in the histogram. The gene expres-
sion was determined through qPCR analysis of the liver samples. The expression of each gene
was normalized using Biogazelle’s qBasePLUS software with Gapdh and Gus-beta as reference
genes. The columns represent CNRQmeans ± SEM (n = 8 animals per group). The significance
of differences between groups was evaluated using one-way ANOVA for each gene. P<0.05,
P<0.01 denote significant differences compared with the corresponding STD-fed group.
(TIF)
S2 Fig. Socs3 and Pias3 expression in liver of HFD-fed mice treated chronically with rIL-6.
Representative western blot analysis for Socs3 and Pias3 proteins out of five samples per group
(STD, HFD and HFD+rIL-6). The corresponding expression of actin is shown as loading con-
trol per lane. The ratios for Socs3/actin and Pias3/actin determined through densitometry are
shown in the histogram below. The values represent the means ± SEM. The significance of dif-
ferences between groups was evaluated using one-way ANOVA.
(TIF)
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